Neurogene Inc. Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain
Neurogene Inc. (NGNE) had Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain of $0 as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt Securities, Held-to-Maturity, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain · last filed 2026-08-11
- 2026-06-30: Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain $0.00.
- 2026-03-31: Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain $14.00K.
- 2025-12-31: Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain $135.00K.
- 2025-09-30: Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain $147.00K.
| Period end | Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 |
| 2026-03-31 | $14.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $135.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $147.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $24.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $76.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $126.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | $172.00K 10-Q · filed 2024-11-18 |
| 2024-06-30 | $1.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 |
| 2023-12-31 | $16.00K 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |